Few drugs in the market are not approved by the authorities and can be life-threatening.
Axis Bank has reported a better-than-expected 18.4 per cent increase in quarterly net profit.
ICICI Bank puts up a good show in Q4.
Infosys has been making bets on automation and other high-margin services like artificial intelligence to regain some ground
Banks are pushing into credit cards and personal loans, using blanket advertising, cold call campaigns and even sending employees to malls to lure customers.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Lenders fret over stubbornly weak credit growth and still high funding costs.
India's state banks are under pressure to improve profitability.
State-owned banks have amassed bad loans faster than private sector lenders.
RBI moves to restrict bank exposure to corporate loans.
Sun Pharma open to large acquisitions post Ranbaxy.
The SBI auction will be the biggest nationwide online sale.
MUDRA bank will help microfinancing firms to lend more.
They need to have 15 years of mainstream banking experience
Telecoms investor Aditya Birla Nuvo Ltd and retailer Future Group were among the first big names to apply for licenses to run so-called payments banks
Trouble at a single bank among the top five most connected lenders could wipe out nearly 50% of Tier I capital
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
The new drugs to come under price control include commonly-used antibiotics and painkillers
India's antitrust regulator has approved Sun-Ranbaxy deal, subject to the companies divesting seven products.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances